Andrew Galler

speaker

96 appearances 1 recordings 1 series first heard Feb 2026 last heard 3 Feb

Andrew Galler’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Precision Cardiology With Cytokinetics · 3 Feb 2026 podcast

And I know that they're, I think they're CYP450 inhibitors and inducers, increasing the risk of heart failure.

Has your market research identified any drugs in this class that are kind of used pretty prevalently in the HCM population?

It would be interesting to watch the initial days of the mycorrhizal launch here.

But maybe moving away from obstructive HCM to non-obstructive HCM, you're currently running the Acacia HCM study for this indication.

I think just from a high level in the past, you've said the HCM market is 50-50 obstructive and non-obstructive.

But do you think there's any ways these patient populations differ in terms of symptom severity, willingness to seek treatment, diagnosis rates, and so on and so forth, just thinking about the market dynamic?

And I'm glad you touched on Odyssey HCM and also the different set of symptoms between obstructive and non-obstructive.

Because when I look at other trials in non-obstructive, it seems like the placebo response rates on measures like the Kansas City cardiomyopathy questionnaire appear to be directionally greater than in obstructive HCM.

So how do you think about controlling this as a risk for acacia?

So as we think about read-throughs from your Phase 2 study, I think it was Redwood HCM.

How, I mean, obviously it's a very small, it was a relatively small trial, less than 200 patients sort of Phase 2.

Can you speak to how representative that trial population was of the non-obstructive HCM population and any potential differences you might see in baseline characteristics in Acacia?

Yeah.

There seems like you think two areas of differentiation for Acacia on trial conduct is going to be enrollment screening and then also conduct of the KCCQ.

Yeah.

And I think one of the key difference from when we look at Redwood to Acacia and the translation, you're going from, you're going now to 48 weeks of treatment.

So how do you see KCTQ developing from their Redwood time point to the Acacia time point?

Is there a potential for a ceiling effect is what I'm kind of getting at or a plateau?

So keep in mind that

Okay, great.

Showing 61–80 of 96 · page 4 of 5